A lyophilization method was developed to locally release adenoviral vectors directly from biomaterials for in situ regenerative gene therapy. Adenovirus expressing a b-galactosidase reporter gene (AdLacZ) was mixed with different excipient formulations and lyophilized on hydroxyapatite (HA) disks followed by fibroblasts culturing and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) staining, suggesting 1 M sucrose in phosphate-buffered saline had best viability. Adenovirus release studies showed that greater than 30% virus remained on the material surface up to 16 h. Lyophilized adenovirus could be precisely localized in defined patterns and the transduction efficiency was also improved. To determine if the lyophilization formulations could preserve viral bioactivity, the lyophilized AdLacZ was tested after being stored at varying temperatures. Bioactivity of adenovirus lyophilized on HA was maintained for greater than 6 months when stored at À801C. In vivo studies were performed using an adenovirus encoding BMP-2 (AdBMP-2). AdBMP-2 was lyophilized in gelatin sponges and placed into rat critical-size calvarial defects for 5 weeks. Micro-computed tomography (m-CT) analysis demonstrated that free-form delivery of AdBMP-2 had only modest effects on bone formation. In contrast, AdBMP-2 lyophilized in gelatin sponges led to more than 80% regeneration of critical-size calvarial defects. Gene Therapy (2007) 14, 891-901.
Introduction
The development of effective bone regeneration strategies is an important health-care issue. Through tissue engineering applications, wound sites may be repaired or regenerated by mimicking natural developmental healing processes. Appropriate biological signals with the correct temporal and spatial release profile may recruit host cells to wound sites and direct new tissue development within designed biomaterial scaffolds. Therefore, controlling the release of bioactive factors from biomaterials will play an essential role for bone regeneration.
Protein-based bioactive factor delivery methods have typically used an encapsulated carrier with scaffolds for controlled release that are designed to control the release rate of growth factors. [1] [2] [3] However, physiologic release patterns have been difficult to attain. In addition, implanted growth factors may be enzymatically inactivated and unable to maintain optimal activity during the desired therapeutic period. The high cost of milligram dosage needed may also be impractical. 4, 5 Therefore, gene therapy may provide an alternative approach by which virally transduced cells function as bioreactors to endogenously produce growth factors. This approach may improve control over the timing, distribution and the level of multiple regenerative factor delivery. Cells transduced with genes encoding regenerative factors can secrete signaling molecules to recruit and modify cell behavior. 6 Both viral and nonviral vectors may be used as vehicles to deliver target genes to cells. Compared to nonviral vectors, viral vectors exhibit much greater transduction efficiency. 7 In an ex vivo gene therapy approach, cells are collected, transduced and cultured in vitro before in vivo implantation. 8 Although the majority of virus particles can be excluded before transplantation to avoid risk systemic infection, harvesting and culturing cells from patients may render this approach impractical for many applications. Furthermore, in vitro cell culture expansion may take several months, which is also expensive and time consuming for immediate clinical scenarios. Therefore, a strategy that combines bioengineered scaffolds with in situ virus delivery may overcome many of these drawbacks.
The controlled release of viral vectors from bioengineered scaffolds may reduce the need for cell-based regenerative approaches and allow for precise spatial control of cell signaling factors. However, the controlled delivery of viruses from scaffolds is difficult because the viruses are labile. In addition, viral vectors may diffuse immediately after implantation and infect cells not in the target site. Therefore, we sought to develop methods to control the spatial release of adenoviral vectors for bone tissue engineering.
Lyophilization is an efficient method to improve the stability of labile biopharmaceuticals. Virus bioactivity can be preserved for long-term storage and lyophilized virus has been coated on allografts to mediate in vivo gene transfer. 9, 10 In addition, localized virus delivery can enhance transduction efficiency. 11 Therefore, we hypothesized that an appropriate lyophilization method could localize active virus on biomaterial surfaces that could not only maintain viral bioactivity but also restrict virus on the material surfaces to improve cell transduction. This virus delivery method could then be applied to biological scaffolds for bone regeneration.
Results

Lyophilization preserves virus bioactivity and localizes virus on HA material surfaces
Lyophilization of adenovirus is currently the methods of choice for long-term storage of virus stocks. 12 We therefore hypothesized that the appropriate formula could be used to retain virus on material surfaces for localized gene delivery. Three different excipient formulations were tested. An adenovirus expressing b-galactosidase (AdLacZ) as a reporter gene was used to examine virus bioactivity and infection performance. For the suspension lyophilization experiment, adenovirus lyophilized in phosphate-buffered saline (PBS) only negative control (NC), always lost its bioactivity during lyophilization (Figure 1a ). An excipient containing 10 mg/ml sucrose and mannitol in PBS (Suc/Man) performed better than the NC, but was not as robust as the two other formulations. Virus bioactivity was maintained at the highest level when mixed with 40 mg/ ml sucrose and mannitol with 0.001% Span 20 in PBS (Suc/Man/Span) or in PBS with 1 M sucrose (1M-Suc). These two formulae preserved bioactivities equivalent to the positive control (PC), virus without lyophilization. In addition, virus lyophilized on material surfaces in 1M-Suc and Suc/Man/Span both enhanced virus infection performance compared to the PC in the surface lyophilization experiments (Figure 1b) . These findings suggested that the appropriate formulae can concentrate and localize adenovirus on material surfaces to improve transduction efficiency. Although these two formulae can both maintain viral bioactivity and localize virus infection, we chose 1 M sucrose in PBS for our following lyophilization experiments because of its ease of preparation. In addition, sucrose is a carbohydrate molecule that contains ambient hydroxyl groups. Hydrogen bonds formed between the material surfaces and viral capsid may facilitate virus adhesion.
After the optimal lyophilization formula was determined, AdLacZ adenovirus was lyophilized on glass cover slips in defined patterns. Fibroblast were cultured on these cover slips for 2 days then stained with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal). These cells were examined under a phase contrast microscope before X-gal staining to confirm that they grew to confluence on the slips. We observed that cells were only infected in the pre-defined 'U M' pattern. This provided strong evidence that adenovirus lyophilized on material surfaces can be precisely localized in a specific pattern and maintain its bioactivity (Figure 1c) . Determination of optimal excipient formulations. Lyophilization excipient formulations were compared for their ability to preserve bioactivity of lyophilized adenovirus and localize virus infection. AdLacZ was diluted in different excipient formulations for lyophilization. After infection of fibroblasts, X-gal staining was applied to determine recovery and infection efficiency. Three different excipent formulae were examined (Suc/Man/Span: 40 mg/ml sucrose, 40 mg/ml mannitol and 0.001% Span 20 in PBS; Suc/Man: 10 mg/ml sucrose and 10 mg/ml mannitol in PBS; 1M-Suc: 1 M sucrose in PBS). AdLacZ lyophilized in PBS alone was treated as NC and non-lyophilized virus served as the PC. (a) In suspension lyophilization, virus was lyophilized, then reconstitute in medium to infect cells in the free form. (b) Virus lyophilized on HA-disk surfaces for cell infection. (c) AdLacZ lyophilized with 1 M sucrose in PBS was added on glass cover slips in specific patterns 'U' and 'M'. After culturing with confluent C4 fibroblasts on the surface, X-gal staining was applied to demonstrate the transduction regions. Only cells in the pattern sites were infected, suggesting the lyophilized virus was under precisely spatial control.
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Virus lyophilized on material surfaces enhances transduction efficiency
Two environments with different virus concentrations were tested to evaluate infection efficiency of adenovirus delivered on biomaterials. For both tissue culture wells and HA disks, no differences were observed between before and after lyophilization treatment if virus suspended in the free form was used for infection (Figure 2a and b). However, if virus was lyophilized on HA disks, infection efficiency was significantly improved ( Figure  2b ). The transduced cell area of surface lyophilization was nearly double than that of the suspended lyophilization group. These data suggest that lyophilized virus on biomaterials can effectively decrease the concentration of virus needed for infection. We hypothesized that lyophilized virus was localized and concentrated on the material surface and thus we designed a low-volume infection to mimic this situation. The virus lyophilized on HA disks had better infection performance than the free-form group (Figure 2c ). This result demonstrated that lyophilization can enhance the virus infection. However, there was no significant difference between these two groups when infected by the low-volume procedure (Figure 2d ). Moreover, virus in low-volume infection always had a higher transduction efficiency than the higher volume condition.
Lyophilized virus can be locally delivered on material surfaces
The release of viral DNA from HA surface was determined in vitro ( Figure 3) . Lyophilized virus released rapidly in culture medium. In this aqueous environment, about 60% virus was released in the first hour; however, the release was subsequently slower. Approximately 30% of the virus was maintained on the HA-disk surfaces after 16 h. Because one-third of the virus could be retained on the material surface without releasing, this result is consistent with our hypothesis that lyophilized virus has a more robust infection performance owing to its concentration on material surfaces.
Bioactivity of lyophilized virus on biomaterials can be preserved for long-term storage
To determine if lyophilization may effectively extend virus survival rates on biomaterial surfaces, we lyophilized AdLacZ in 1 M sucrose, and then reconstituted it in culture medium at different time points to assess the decline of viability at different temperatures. At 41C, virus infection was detectable for 3 months. In the frozen environment, À20 and À801C, virus bioactivities continuously decreased in the early period. However, after 1 month storage, the activity equilibrized and was Localized virus delivery for in situ gene therapy W-W Hu et al maintained up to at least 6 months. The survival rates of À20 and À801C were 4972 and 6572%, respectively ( Figure 4a ). In contrast, the control group consisting of virus in PBS lost its bioactivity rapidly. No active virus was detected after 2 weeks when stored at 41C. Even at a À801C storage temperature, there was only 40% virus bioactivity ( Figure 4b ).
We next evaluated viral bioactivity when AdLacZ was lyophilized on HA-disk surfaces. The viability trends of surface lyophilized virus were similar to the suspension lyophilization group (Figure 4c ). First, the bioactivity was 350710% of the PC. This was likely due to the localized infection effect. Similar to suspension lyophilization, surface lyophilized virus exhibited a decline in bioactivity in the first month. At 41C, virus was maintained for 3 months. This was in contrast to surface lyophilized constructs stored at lower temperatures. In these conditions, robust virus activity was sustained and the survival rates were 140728 and 274732% when viruses were stored at À20 and À801C, respectively. The high survival rates maintained at frozen conditions suggested that virus lyophilized with biomaterials could be stable for long-term storage.
Bone regeneration in critical-size defects is improved by localizing in vivo gene therapy
Because adenovirus could be localized on HA-disk surfaces to enhance cell infection, we sought to determine if virus localization could be effective for clinical relevant orthotopic bone regeneration. Critical-size defects provide a convenient nonloaded model to evaluate bone repair strategies as the defect cannot spontaneously heal during the lifetime of the animal. 13 Micro-computed tomography (m-CT) was used to quantify bone volume fraction (BVF), bone mineral density (BMD) and histomorphometric analysis was performed to determine bone area fraction (BAF) in the defect region. Free adenovirus encoding BMP-2 (AdBMP-2) was treated as the PC group and lyophilized AdLacZ as the NC.
m-CT 3D analysis demonstrated that the lyophilized AdLacZ group had only minimal bone growth at the edges of the defect (Figure 5a ). A BVF of 14.574.8% and a BAF of 16.875.4% indicated that critical-size defects may not spontaneously heal using gelatin scaffolds without osteoinductive BMPs (Figure 5b and c). The newly formed bone in the free-form AdBMP-2 group was mainly distributed along the defect edge with occasional isolated bony islands localized in the center region ( Figure 5a ). The BVF and BAF were 43.8713.6% and 43.1714.1%, respectively, which indicated the free virus induced modest bone regeneration (Figure 5b and c). In contrast, the lyophilized AdBMP-2 group had almost double the bone growth than the free-form group in terms of both BVF and BAF (88.7723.5% and 75.4715.0%), demonstrating that transduction can be improved to induce more bone regeneration in orthotopic defects by localizing adenovirus on biomaterials (Figure 5b and c) . m-CT images of the lyophilization group also suggested that new bone was evenly distributed to cover the defects and lead to excellent , which is significantly lower than the other three groups (Po0.01) (Figure 5d ). Interestingly, although lyophilized AdBMP-2 had significantly higher BMD than free AdBMP-2 group (250741 vs 178742 mg/cm 3 ), the difference was not as obvious as BVF and BAF (Po0.05).
By histologic analysis, only dense fibrous connective tissue with minimal osteogenesis was found in the lyophilized AdLacZ-treated defects (Figure 6a ). Some small osseous islands were observed in the free AdBMP-2 group (Figure 6b ). However, extensive bone regeneration was always observed in the lyophilized AdBMP-2 group (Figure 6c) . Nearly all the defect space was filled with confluent bone. The newly formed bone had woven or immature appearances and exhibited embedded osteocytes and hematopoietic marrow cells. The newly formed bone was osseointegrated with the native bone and the margins were difficult to identify (Figure 6c ). Because the new bone was not uniformly distributed in the defects, histomorphometry was not performed from these slides to avoid potential bias. BVF and BAF from m-CT analysis may provide a more valid comparison to quantify the fraction of new bone formation among experimental groups. The agreement of histology and m-CT results confirmed our hypothesis that virus lyophilization can effectively improve transduction for in situ regenerative gene therapy.
Discussion
Regenerative gene therapy differs from traditional gene therapy, which was originally conceived as a means of correcting hereditary disorders 14 and aims to facilitation tissue regeneration by transducing cells that may provide sustained levels of biologically active molecules at a targeted site. 15 Therapeutic genes may be delivered by either ex vivo or in vivo approaches to express bioactive factors. Compared to ex vivo gene therapy, in vivo gene therapy may avoid the need for two surgical procedures (biopsy harvest and transplantation) which may cause morbidity at donor sites and also has a higher potential to transmit disease. Moreover, the complex in vitro cell-processing steps may also be eliminated (purification, amplification, transduction and then implantation). For in vivo gene therapy, there are several hurdles that must be overcome: (1) vectors need to be localized in wound sites to minimalize host immune response, (2) the transgene expression should be maintained for a sufficient period of time, but must be inactivated once the therapeutic response had been achieved and (3) viral vectors should safely and efficiently infect host cells to reduce side effects. 15 Adenoviral vectors are widely used as vehicles to deliver genetic material for in vivo gene therapy. They have extremely high transduction efficiencies and can accommodate large cDNA fragments. 7 Cell transduction is feasible in most cell types, and thus adenovirus can be broadly used to transduce different tissues. The inability to integrate into the host genome ensures that transgene expression is transient, which is preferable for bone healing because continued gene expression following complete defect regeneration is unnecessary and possibly pathogenic. 16 Therefore, adenovirus is a good candidate vector for in vivo regenerative gene therapy. However, a major drawback of adenoviral vectors is that the expression of viral protein may induce a significant 
Directly injecting AdBMP-2 in thigh musculature results in endochondral bone formation in athymic nude rats; however, little to no bone is regenerated in immunocompetent rats. 17 Many research groups have shown the inability of Ad-BMP2 to induce in vivo bone formation in immunocompetent animals. [17] [18] [19] [20] [21] [22] Consequently, different approaches have been investigated to reduce the vector-induced immunogenicity. Immunosuppression drugs, such as cyclophosphamide, have been used to restrain the immune response, 22 and the use of adeno-associated virus (AAV), with a lower viral protein expression, may also decrease antigenicity. 10, 23 Another strategy is to reduce vector dosage by improving transduction efficiency. 24 Adenovirus internalization into host cells can be enhanced by complexing with fibroblast growth factor-2 (FGF-2) through mouse monoclonal neutralizing anti-knob antibody (Fab 0 ), and hence, fewer viral particles are needed for in vivo transduction. 25 Using a similar strategy, we hypothesized that adenovirus could be concentrated in defects by immobilization on biomaterial scaffolds, and thus the effective vector dosage would be greatly reduced to improve efficiency for regenerative gene therapy.
In this study, we examined the hypothesis that adenovirus lyophilized on biomaterial surfaces can be localized for in situ transduction. We found that 1 M sucrose in PBS was the optimal lyophilization formula that can effectively restrict adenovirus on material surfaces. These lyophilized viral particles can be precisely localized on the target site. Long-term storage of the virus-material complex was also feasible. In addition, the critical-size calvarial defect model revealed that Localized virus delivery for in situ gene therapy W-W Hu et al bone regeneration can be effectively enhanced when AdBMP-2 is lyophilized in gelatin sponges, suggesting lyophilization may be an improved strategy for in vivo regeneration gene therapy. Delivering vectors by injection or inhalation, known as systemic or bolus delivery, leads to the presence of vector in the target cell population for a brief time before clearance. By this method of administration, only a fraction of the vector is internalized. 26, 27 This is problematic because the target cell population must often be exposed to signaling factors throughout the entire course of repair. 28 In addition, in order to achieve therapeutic goals, a burst of extremely high viral titers may need to be administrated and this risks cytotoxicity and inflammation.
9,29 Therefore, polymeric release and substratemediated delivery are two modified delivery systems that may overcome this mass transportation limitation. 30 Polymeric release methods incorporate viral vectors in the polymer matrix and controls release by polymer degradation. 16, 24, [31] [32] [33] Viral vectors may release slowly to prolong therapeutic protein expression. 16 In addition, because the viral concentration decreases with increasing distance from the target location, it may create a gradient of transduction and transgene expression. Therefore, recruited cells can be directed by the therapeutic protein gradient. In contrast, substrate-mediated delivery is designed to immobilize vectors on biomaterial substrates for direct exposure in a cellular environment. As these vectors can only infect cells on the material surface, it may restrict transduction regions and spatially control the therapeutic protein expression in the immediate vicinity of the substrate. 34 Because the vectors are concentrated on the material surface, there may be a reduction in the amount of virus required compared to bolus delivery. 35 This may increase transduction efficiency and decrease cytotoxicity. 36, 37 Binding forces between the substrate materials and vectors may play an important role in determining the infection performance; strongly immobilized vectors may limit cellular internalization, whereas weakly immobilized vectors will not be retained on the surface for presentation to cells. 30 Adenovirus lyophilization is similar to substratemediated delivery because the viral particles adhere to the material surface before implantation. In an aqueous environment, virus released rapidly in the early stages, whereas it slowed down and then plateaued so that almost 1/3 virus was maintained on the surface. Because only a small fraction of virus particles remained on the material surface, this suggests that the binding force generated by lyophilization in sucrose was not strong. From this in vitro releasing behavior we deduce the distribution of the virus lyophilized on biomaterials should be between that of polymer release and subtractmediate delivery.
To determine if the virus lyophilized on material surfaces could be concentrated to enhance transduction efficiency, we designed an experiment to transduce cells in low volume conditions that force viruses to remain in close proximity to the material surface. 38, 39 Thus the free virus group may perform similar to the lyophilization group in a limited medium environment. Because reducing the infection volume is impractical for in vivo delivery, we localized adenovirus on the material surface by lyophilizing with appropriate excipients that enhanced virus adhesion. In the experiment with a high volume environment, adenovirus lyophilized on HA disks improved infection efficiency. These data suggest that surface lyophilization reduced adenovirus diffusion to localize virus distribution for cell transduction.
The long-term storage experiments indicate that lyophilized virus may lose bioactivity at 41C with time. However, in a frozen environment (À20 and À801C) the viability declined only slightly in the first month and then remained stable for longer than 6 months. Moisture may be the major reason of the instability for storage. The adenovirus was a solid crystal form when it was completely dried by lyophilization. However, it turned to a gel-like form when stored at 41C, suggesting that the lyophilized virus was rehydrated with moisture. The moisture content of the lyophilized cake is the most important factor for the recovery of adenovirus. [40] [41] [42] Residual water may disrupt excipient-protein interactions that stabilize conformation in the dry state and therefore interfere with the conformation protection offered by the excipient formulation.
12, 43 Because we stored our lyophilized virus in non-sealing scintillation vials, it may have allowed the surrounding moisture to affect the lyophilized virus leading to virus degradation at 41C. In contrast, rehydration can be effectively inhibited at À20 and À801C. The frozen environment should be able to effectively reduce moisture and thus avoid the further virus degradation in the following period. Therefore, the moisture could be eliminated by sealing storage bottles or using desiccant for dehydration to preserve viral bioactivity for long-term storage. An appropriately dehydrated environment may even maintain viral bioactivity longer than 1 year at 41C. 12 For orthotopic bone regeneration, AdBMP-2 was lyophilized in gelatin sponges to evaluate new bone growth in critical-size calvarial defects. There was almost no bone formation in NC groups, suggesting that the gelatin sponge is not osteoconductive. New bone formation was mainly due to the osteoinductive effects of AdBMP-2 transduction. Three quantitative m-CT methods were performed to evaluate bone regeneration in these defects. BVF was mainly used to compare the absolute quantity of bone regenerated in defects, whereas the BAF demonstrated the mineralized tissue coverage in defects. For therapeutic purposes, BAF may be more reflective of the regeneration effect than BVF because more bony area covering the defects in the early stage may lead to better bone filling with time. The trends for BVF and BAF were consistent in our experiments. The extremely high correlation coefficients of all three groups (r40.9) suggested that the regenerated bone was evenly distributed in the defects. Sagittal m-CT images also illustrated that mineral tissue growth filled in defects with excellent spatial control (Figure 5a ). Compared to the surrounding bone, BMD of the new growth bone was apparently less than that of the nearby normal compact bone which is approximately between 400-500 mg/cm 3 , indicating the function of AdBMP-2 in orthotopic bone healing affects bone volume more than bone density in the time frame of this study. From the BVF and BAF assessments, the regenerated bone covered greater than 80% of defects by lyophilized AdBMP-2. This was much improved over the method of suspending virus in the biomaterials. 
Histology images illustrated the newly formed bone in the lyophilized AdBMP-2 group was osseointegrated with the native bone margin. Contrasted to the free AdBMP-2 group in which abundant fibrous tissue filled in the defects, there was also bone marrow in defects treated with lyophilized AdBMP-2. The new bone was only distributed in defects, suggesting that bone regeneration was enhanced and excellent spatial control was achieved. These promising results demonstrate that lyophilized AdBMP-2 can effectively facilitate criticalsize defects healing.
Lyophilization had been applied to incorporate recombinant AAV (rAAV) encoding receptor activator of nuclear factor kB ligand and vascular endothelial growth factor on to the cortical surface of femoral allografts for transplantation with 1% sorbitol-PBS. 10 In vitro releasing experiments resulted in a mosaic distribution of transduced cells suggesting that aqueous environment may release virus by free diffusion in the culture medium before infection. The transduction efficiency was modest; only 1-5% cells in the immediate proximity to the allografts were infected. This suggests that the rapid diffusion of lyophilized virus in the aqueous environment may decrease local virus concentration and reduce the transduction efficiency in vivo. By using sucrose as an excipient for lyophilization, we demonstrated that virus can be precisely localized on biomaterial surfaces to transduce cells in a specific pattern site. This suggests that sucrose may enhance virus adhesion on material surfaces, which may facilitate spatial control of infection for implantation. Furthermore, sucrose is a common carbohydrate in physiological environment. It should be safe without cytotoxicity for in vivo transplantation. As the slower release can concentrate virus on material surfaces, virus administration may be reduced to decrease the risk of systemic infection.
In summary, an effective in vivo regenerative gene therapy strategy was developed for localized viral delivery. Adenovirus lyophilized on biomaterial surfaces with 1 M sucrose in PBS can enhance virus transductaion efficiency in vitro and in vivo. Lyophilized adenovirus can be localized and concentrated on scaffolds to effectively reduce virus concentration for bone regeneration and may diminish the risks of systemic infection and immune response. Viral bioactivity may also be maintained on biomaterials after long-term storage. This observation may allow a lyophilized adenovirus to be incorporated with biomaterials as a pre-made construct to be used at time of surgery. Together, these results demonstrate that this approach may have potential for applications with biomaterials for in situ regenerative gene therapy.
Materials and methods
Cell culture and virus generation
C4 fibroblast cells (ATCC, Manassas, VA, USA) were cultured in alpha-minimal essential medium (a-MEM, Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Gibco) and penicillin (100 unit/ml)-streptomycin (100 mg/ml) (Gibco). Cells were seeded at density of 20 000 cells/cm 2 . An adenovirus encoding the bacterial b-galactosidase gene (AdRSVntLacZ) and nuclear localization sequence was used as a reporter gene. The virus used for in vivo application, AdCMV-BMP-2, was a recombinant virus with the E1 and E3 genes deleted and contained the mouse BMP-2 gene, which was constructed using Cre/lox recombination as previously described. 44 Assessment for in vitro virus transduction C4 fibroblasts were cultured in 48-well cell culture cluster dishes (Corning, NY, USA) at a density of 2 Â 10 4 per well in 350 ml culture medium for the AdLacZ virus infection. After 2 days incubation at 371C, the cells were fixed in 1% glutaraldehyde for one half hour and then washed three times with PBS. The 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside staining solution, 0.2% X-gal (Invitrogen, Frederick, MD, USA) in N,N-dimethyl formamide with 2 mM MgCl 2 , 5 mM K 4 Fe(CN) 6 _3H 2 O, 5 mM K 3 Fe(CN) 6 in Hank's buffered salt solution (HBSS) (all Sigma), was prepared and 350 ml was added for 371C incubation overnight then rinsed once more with HBSS. Because cells infected with active virus expressed b-galactosidase and hydrolyzed X-gal to form an intense blue precipitate, the stained area was used as an indication of viral bioactivity. The blue area was digitally captured under an SMZ-U stereoscopic zoom microscope (Nikon, Melville, NY, USA) with a DC290 digital camera (Eastman Kodak, Rochester, NY, USA). The blue pixels in the image were analysed by Scion Image software (Scion, Frederick, MD, USA). Color images were converted to gray scale and then thresholded to mark the pixel area. Pixel number was counted to indicate the level of cell infection.
Virus lyophilization formulation
Different excipients were tested using methods established for long-term adenovirus storage. 12 Two different lyophilization conditions, suspension lyophilization and surface lyophilization, were tested. For suspension lyophilization, AdLacZ was diluted to 5 Â 10 8 PFU/ml (PFU: plaque forming unit), and 10 ml placed in a microcentrifuge tube. For surface lyophilization, 2 ml AdLacZ was diluted to 2.5 Â 10 9 PFU/ml and placed on 5 mm diameter hydroxyapatite (HA) disks. The sintered HA-disk surfaces were smooth and dense. These dense surfaces inhibited virus and cell migration into the scaffold and thus the experimental environment was limited to the top of the disk. Both groups were incubated at À801C for 2 h and then were lyophilized in a freeze dryer (Virtis, Gardiner, NY, USA) at À78.51C and 100 mTorr for 24 h. The lyophilized virus was reconstituted in culture medium for the suspension lyophilization group. Subsequently, 1 Â 10 4 C4 fibroblasts were seeded to make a final multiplicity of infection (MOI) of 500. AdLacZ lyophilized in PBS alone was treated as a NC and nonlyophilized virus served as the positive control. After 2 days infection, X-gal staining was performed to evaluate preservation of virus bioactivity after lyophilization. The formula with the best performance was used for all subsequent experiments.
After the optimal formula was determined, a pattern assay was tested to determine if lyophilization could precisely localize the virus on a material surface for infection. AdLacZ (10 7 PFU/glass slide) was added by micropipette in the pattern of the letters 'U' and 'M' on glass cover slips. After 1 day lyophilization, the slides were placed in Petri dishes and cultured with C4 fibroblasts for 2 days to obtain a confluent layer of cells 
Efficacy of transduction by virus localization
To determine if the virus lyophilized on biomaterial surfaces could be localized and enhance transduction, viruses were lyophilized for 24 h and infected cells by two methods: (1) virus lyophilized in microcentrifuge tubes and then reconstituted in culture medium to infect cells as a free form, or (2) virus lyophilized on HA disks followed by culturing cells on the surface directly. Virus without lyophilization was used as a positive control. X-gal staining after a 2-day cell infection was applied to evaluate the transduction efficiency. In addition, a low-volume infection experiment was performed to simulate the lyophilized virus infection on material surfaces. AdLacZ was diluted to 5 Â 10 9 or 1 Â 10 10 PFU/ml and 2 ml was added to HA disks and lyophilized for 24 h. C4 fibroblasts were cultured on the material surface to make the final infection 500 or 1000 MOI. The same amount of virus was lyophilized and then reconstituted in culture medium to infect cells directly in the free-form method. Two different infection volumes were used during the infections: (1) regular volume: 350 ml medium were added in the culture wells for 2 days infection and (2) low volume: 20 ml medium were added on the HA disks surface first for 3 h infection, then 330 ml medium was added in culture wells and also incubated for 2 days. The infected cells were then stained with X-gal to determine and compare transduction efficiency.
Release behavior of virus lyophilized on material surfaces
Adenovirus was lyophilized on HA disks for 24 h and then placed in 48-well culture plates with 350 ml culture medium at 371C to simulate the in vitro infection. The medium was sampled (45 ml) at 1, 2, 4, 8, 15, 30 min and 1, 2, 4, 8 and 16 h. Non-lyophilized virus was used as a standard. The supernatant was treated with 5 ml of 0.5% sodium dodecyl sulfate in TE buffer (10 mM Tris-HCl, pH ¼ 7.5, 1 mM ethylenediaminetetraacetic acid) at room temperature for 15 min to lyse the viral capsid. The fluorescent dye, PicoGreen (Promega, WI, USA), which can selectively bind viral DNA was used to quantify viral DNA. Twenty microliters of diluted lysed viral standards or samples were added to 96-well microplates. PicroGreen reagent was diluted 360-fold in TE buffer and 180 ml was added to each well. After 5 min dark incubation, the viral DNA-PicoGreen complex was read on a microplate spectrofluorometer (Gemini XPS, Molecular Devices, Sunnyvale, CA, USA) with 485 nm and 538 nm wavelength setting for excitation and emission, respectively. 21 Preservation of viral bioactivity after long-term storage AdLacZ was lyophilized either in microcentrifuge tubes or on HA disks for 24 h. Viruses in PBS without lyophilization were also accompanied as negative control. Samples were stored at À80, À20, or 41C. After 1, 2 weeks, and 1, 3 and 6 months storage, lyophilized virus in microcentrifuge tubes was reconstituted in culture medium and then used to infect C4 cells on HA disks. Virus lyophilized on HA disks were also placed in culture wells for cell infection. C4 fibroblasts were cultured at a density of 1 Â 10 4 cells/well and the final infection concentration was 500 MOI. Fresh virus without lyophilization was compared as standard for the X-gal assay to determine the change of viral bioactivity with time.
Orthotopic bone regeneration for rat calvarial criticalsize defects Gelfoam, a gelatin sponge (Pfizer, New York City, NY, USA), was used as a biomaterial scaffold and BMP-2 was the target gene to deliver by adenovirus for bone regeneration. Sponges were cut to fit 8 mm calvarial defects and were hydrated in PBS before adenovirus loading. For the virus lyophilization groups, 20 ml adenovirus in PBS with 1 M sucrose was loaded on to the gelatin scaffolds at final concentration of 10 8 PFU then freeze dried for 24 h. A free AdBMP-2 group was also prepared with the same virus concentration in PBS before surgery. Virus concentration was determined by a pilot experiment to titrate virus concentrations from 10 7 to 10 9 PFU for both free and lyophilized AdBMP-2 groups. Bone growth was undetectable with 10 7 PFU. In contrast, both lyophilized virus and free-form virus groups exhibited new bone formation if the virus was 10 8 PFU. In experiment when the virus concentrations were greater than 10 8 PFU, there were no differences between groups because this viral titer led to bone overgrowth. Therefore 10 8 PFU was chosen as our effective dose.
Fisher 344 rats (Charles River, Wilmington, MA, USA) weighing 200-250 g were anesthetized by ketamine and xylazine mixture (80 mg/kg ketamine, 10 mg/kg xylazine of body weight). A 3-cm linear incision was made over the calvarium and the periosteum was completely cleared from the surface of the cranium by scraping. A critical-size defect was created using an 8 mm diameter trephine burr with copious PBS irrigation. The calvarial disks were carefully removed and gelatin scaffolds were placed in the defects. The incisions were closed with 4-0 chromic gut sutures (Davis-Geck, Wayne, NJ, USA). Five animals per each group were implanted for 5 weeks, and then scarified for histology and m-CT analysis. All specimens were fixed in buffered zinc-formalin fixative, Z-Fix, for 1 day and then stored in 70% alcohol. Care and use of the laboratory animals followed the guidelines established by the University of Michigan Committee for the Use and Care of Animals.
m-CT 3D reconstruction and bone histomorphometry
Specimens were scanned by m-CT on a MS8-CMR-100 m-CT scanner (EVS Corp, London, ON, Canada) at 10 mm voxel resolution and 80 kV. Then these reconstructed images were analysed by Microview v2.1.0 (GE, Waukesha, WI, USA). Auto-threshold of the tissue density was determined by Microview to define mineralized tissue (bone). Circular regions of 8 mm diameter were cropped as the region of interest (ROI). The BVF was evaluated by the volume ratio of the mineralized tissue in ROI.
The 3-D images were performed as isosurfaces of mineralized tissue, which were defined by the threshold. The superficial views were captured as in Figure 5a , and then the bone covered in defects was captured by Scion Image software (Scion, Frederick, MD, USA). Finally, the Localized virus delivery for in situ gene therapy W-W Hu et al coverage of the regenerated bone was determined as BAF.
Histology assessment
Before histological analysis, specimens were decalcified in 10% formic acid for 2 days. After paraffin embedding, 5 mm sections were prepared from the middle line of defects and stained with hematoxylin and eosin. These tissue sections were visualized with an inverted microscope Eclipse TE300 (Nikon, Melville, NY, USA). The healing effects of orthotropic bone regeneration were evaluated by examining if there were even newly osseous tissue growth, bone-defect margin osseointegration and hematopoietic bone marrows formation in these critical-size calvarial defects.
